このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Policy Responses Against the COVID-19 Pandemic in Latin America

2021年4月27日 更新者:Sebastián Peña、University of Chile

Policy Responses Against the COVID-19 Pandemic in Latin America: Interrupted Series Analyses of Local Governments

Latin America is one of the worst-hit areas from the COVID-19 pandemic worldwide. Policy responses to COVID-19 in Latin America have sought to reduce viral spread, increase the capacity of the health system response, mitigate negative consequences, and strengthen governance. Few studies have examined the effectiveness of COVID-19 policies in Latin America or explored subnational variation in their effectiveness.

In this observational study, the investigators will use a two-stage interrupted time series to estimate the effectiveness of nonpharmaceutical interventions in third-tier subnational units on SARS-COV2 transmission and COVID-19 mortality in Latin America. The investigators will estimate the effects in each local government, and then run a random-effects meta-analysis to obtain pooled effects for each intervention (and combinations of) and heterogeneity estimates. Finally, the investigators will explore potential explanations for the heterogeneity at the local level.

調査の概要

詳細な説明

The COVID-19 pandemic is spreading rapidly worldwide. Latin America, the region with the highest income inequality, remains as one of the worst-hit areas worldwide. Despite accounting for 8.4% of the global population, Latin America has witnessed 20.3% of the total SARS-COV-2 cases and 30.2% of the COVID-19 deaths to date. Several countries in the region are among the worst-hit worldwide. Brazil has had more than 11 million SARS-COV-2 cases and Mexico, Argentina and Colombia have exceeded the 2 million cases each. Similarly, the five most populated countries in the region (Brazil, Argentina, Mexico, Colombia and Peru) exceed 600,000 SARS-COV-2-related deaths. The pandemic reached Latin America later than other continents, and the first case of COVID-19 in the region was reported in Brazil on February 26, followed by a case in Mexico on February 28, 2020 and subsequently spreading throughout the region during March 2020.

Policy responses to COVID-19 in Latin America have sought to reduce viral spread, increase the capacity of the health system response, mitigate negative consequences, and strengthen governance. Effectiveness studies of social distancing policies in China, India, European countries, the United States and worldwide have shown that these appear to be effective to reduce viral transmission.

Despite the heavy burden of the COVID-19 in Latin American countries, there have been few studies examining the effectiveness of COVID-19 policies. Likewise, few studies have explored variation at the local level in the effectiveness of COVID-19 policies. Inequalities in policy effectiveness can arise due to within-country differences at the local level due to their geographical, sociodemographic, mobility patterns, and governance differences. In Latin America, high levels of poverty, urban density, household crowding, lack of safety nets, unemployment and precarious work cluster geographically and coexist with structural inequities in governance and built environments, thus creating barriers for effective compliance with preventive recommendations and for the implementation of well-functioning contact tracing and isolation mechanisms. Understanding the effectiveness of policies at the local level and exploring potential explanations for effect heterogeneity is essential to reduce the burden of the ongoing COVID-19 pandemic and inform the preparedness for future pandemics.

In this study, the investigators aim, first, to estimate the effectiveness of nonpharmaceutical interventions on SARS-COV2 transmission and COVID-19 mortality in Latin America; second, to examine the effect heterogeneity of transmission and mortality at the local level. Third, assuming there is evidence of moderate to substantial heterogeneity at the local level, the investigators aim to explore potential explanations for this heterogeneity. The study will use an interrupted time series method to estimate their effects in each local government, and random effects meta-analysis and meta-regression to obtain pooled effects, heterogeneity estimates and potential explanations.

Methods Design and setting: Natural experiment exploiting the variation in the temporal and spatial implementation of policy interventions, aimed to reduce the spread and mortality of COVID-19 in Latin America. The unit of analysis are local governments, i.e. third-tier administrative levels such as municipalities, districts or cantons.

Eligibility criteria: See below. To date, eligible countries are Argentina, Brazil, Chile, Colombia, Costa Rica, Guatemala, Mexico, Paraguay, and Peru. These countries represent 80.9% of the population in Latin America, and the vast majority of SARS-CoV-2 cases and COVID-19 deaths.

Interventions: Interventions include (i) policies aimed at reducing viral transmission, (ii) policies aimed at increasing the capacity of the health system's response, and (iii) policies aimed at mitigating the negative consequences of the epidemic and potential adverse effects of interventions. We will use the PoliMap taxonomy to categorise the examined policies.

Comparator: Counterfactual outcome defined as the projection of the pre-intervention trend to simulate what would have happened if the policy had not occurred.

Data sources: COVID-19 cases and deaths data, as well as the covariates, from official government sources, such as the Ministry of Health and Ministry of Science and Technology. The intervention information will come from legal documents, official statements, and quantitative accounts from trustable sources.

Covariates: First model at the local level does not include covariates (see below). Second model (i.e. the meta-analysis), we will examine the change in heterogeneity after adjusting for several covariates at the local level. Local level covariates include projected population size in 2020, demographic density, age-structure of the population, household density and socioeconomic status. We will use data from official sources of information, primarily the latest national population census in each included country.

Statistical analysis: See the Statistical Analysis Plan for details on the modelling assumptions. The study will use an interrupted time series design, where each local government acts as its own control. The main strength of this design is its capacity to distinguish the effect of the intervention from secular change. The study will use a Poisson regression to model the count data (for both outcomes) and accounting for overdispersion and secular trends. A full discussion on potential biases and violations of assumptions can be found in the Statistical Analysis Plan.

In a second stage, the investigators will use random effects meta analysis to pool the effect estimates for each intervention or combination of interventions. This analysis informs whether any implemented intervention was effective to reduce COVID-19 cases and deaths and the degree of heterogeneity between the effects at the local level. If there is evidence of moderate to high levels of heterogeneity (defined as higher than 50%), the investigators will also use standard meta-regression techniques to assess whether local level determinants (see Covariates) can explain the observed heterogeneity. The investigators will build the models and test the analytical strategy using publicly available data on COVID-19 cases and deaths from Finland and Sweden from January 1 to March 31.

研究の種類

観察的

入学 (予想される)

10000

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Región Metropolitana
      • Santiago、Región Metropolitana、チリ、8380453
        • Escuela de Salud Pública
        • 副調査官:
          • Helena Morais, MEcon
        • 副調査官:
          • Maria José Monsalves, PhD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 子
  • 大人
  • 高齢者

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

サンプリング方法

確率サンプル

調査対象母集団

The study covers the population of included countries in Latin America. Preliminarily this represents nine countries, covering 80.9% of the total population in Latin America

説明

Inclusion Criteria:

  • Country will be eligible if they are (1) Spanish or Portuguese speaking countries in Latin America, (2) availability of open data at the subnational level for any of the outcomes

Exclusion Criteria:

  • None

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

コホートと介入

グループ/コホート
介入・治療
Social and public health measures against COVID-19
Public Health and Social measures against COVID-19. This group refers to the population exposed to public health and social measures against COVID-19
  1. Viral spread (for both outcomes) 1.1. Total lockdown 1.2 Partial lockdown (geographical, step-wise/graduated response) 1.3 Curfew 1.4 School closure 1.5 Closure of shopping malls, gyms, churches, parks 1.6 Remote work 1.7 Restrictions to national/subnational mobility 1.8 Prohibition of mass gatherings
  2. Health systems response (for COVID-19 deaths outcome) 2.1 Interventions to increase testing capacity 2.2 Interventions to increase the number of ICU/critical beds
  3. Mitigation strategies (for both outcomes) 3.1 Direct social assistance (in-kind/cash) 3.2 Cash transfer 3.3 Withdrawal of pension funds
他の名前:
  • Non-pharmaceutical interventions against COVID-19
Control
The comparator is the pre-intervention period
The comparator is a counterfactual outcome defined as the projection of the pre-intervention trend to simulate what would have happened if the policy had not occurred (see Statistical Analysis Plan for definitions)

この研究は何を測定していますか?

主要な結果の測定

結果測定
時間枠
7-day moving average of daily confirmed cases of COVID-19/SARS-CoV-2
時間枠:Intervention period of up to 30 days (intervention periods lower than 7 days will be considered as a combined set of interventions)
Intervention period of up to 30 days (intervention periods lower than 7 days will be considered as a combined set of interventions)
Time-varying reproductive number of confirmed cases of COVID-19/SARS-CoV-2
時間枠:Intervention period of up to 30 days (intervention periods lower than 7 days will be considered as a combined set of interventions)
Intervention period of up to 30 days (intervention periods lower than 7 days will be considered as a combined set of interventions)
7-day moving average of daily confirmed deaths of COVID-19/SARS-CoV-2
時間枠:Intervention period of up to 30 days (intervention periods lower than 7 days will be considered as a combined set of interventions)
Intervention period of up to 30 days (intervention periods lower than 7 days will be considered as a combined set of interventions)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Sebastián Peña, MD, PhD、Escuela de Salud Pública
  • 主任研究者:Cristóbal Cuadrado, MD, PhD、Escuela de Salud Pública

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (予想される)

2021年4月28日

一次修了 (予想される)

2021年5月31日

研究の完了 (予想される)

2021年5月31日

試験登録日

最初に提出

2021年3月23日

QC基準を満たした最初の提出物

2021年3月24日

最初の投稿 (実際)

2021年3月25日

学習記録の更新

投稿された最後の更新 (実際)

2021年4月28日

QC基準を満たした最後の更新が送信されました

2021年4月27日

最終確認日

2021年4月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

The study uses open access data available at the municipal/district/canton level. The investigators will include the data and statistical code as a Supplementary Appendix in the published papers.

IPD 共有時間枠

The Study Protocol and SAP will be available in the project OSF repository upon publication of the registration in ClinicalTrials.gov. The Statistical code will be published as a Supplementary Appendix with the publish paper or preprint.

IPD 共有アクセス基準

Any interested party can access the data and documents

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • ANALYTIC_CODE

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する